Guest Editors
Prof. Dr. Luis Cano
Email: luiscanoayestas@gmail.com
Affiliation: INRAE, CHU Pontchaillou, UMR 1241 NUMECAN, Universit de Rennes, 35033, France
Homepage:
Research Interests: digital pathology & ai in cancer diagnosis, molecular oncology & biomarkers, hepatocellular carcinoma (HCC) and liver cancer therapeutics, tumor immunology & immunotherapy, neuro-oncology & glioblastoma, translational oncology & precision medicine, experimental models & clinical validation
Summary
Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, remains a major global health burden with limited therapeutic success in advanced stages. Despite recent advances in targeted therapies and immunotherapies, patient prognosis is often poor due to tumor heterogeneity, drug resistance, and underlying liver dysfunction. This special issue explores the dynamic landscape of molecular targets and combinatorial therapeutic strategies in HCC, aiming to bridge preclinical discoveries with clinical applications. Particular emphasis is placed on novel oncogenic drivers, immune checkpoint modulators, epigenetic regulators, and metabolic vulnerabilities. Emerging combination strategiesintegrating kinase inhibitors, immune-based therapies, and RNA-targeted agentsare discussed for their potential to overcome monotherapy limitations. Furthermore, the role of multi-omics profiling, artificial intelligence, and spatial transcriptomics in identifying predictive biomarkers and therapeutic synergies is critically examined. By highlighting translational insights and future directions, this issue aims to catalyze the development of more effective, personalized interventions for liver cancer patients.
Keywords
hepatocellular carcinoma, molecular targets, combination therapy, immunotherapy, targeted therapy, biomarkers, drug resistance, tumor heterogeneity, kinase inhibitors, RNA therapeutics, spatial transcriptomics, precision oncology
Published Papers
Login
Register
Submit a Paper
Propose a Special lssue